HCW Biologics Inc.
HCWBHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. At a $2.5M market cap, HCW Biologics Inc. ranks as a micro-cap company within healthcare. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Market Cap
$2.5M
Beta
2.42
P/E (TTM)
—
P/E (Fwd)
-2.00
EPS (TTM)
$-18.34
EPS (Fwd)
$-0.55
ROE
-151.4%
ROA
-13.9%
Cash
$741,324
Total Debt
$6.6M
Free CF
-$11.7M
52W Change
-95.2%
Annual Financials
Cash vs Debt
Where HCWB stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, HCWB finished 69.17% below its 150-day moving average ($3.99) and 71.92% below its 200-day moving average ($4.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is HCWB overbought or oversold?
At the October 20, 2026 close, HCWB's RSI(14) was 17.5, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
HCW Biologics Inc. carries $6.6M in total debt against $741K in cash reserves — debt is roughly 8.9x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company is burning cash, with free cash flow at -$11.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -151.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $6.7M (2022) to $54K (2025), a 99% decline worth watching.
A beta of 2.42 means HCWB is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. HCW Biologics Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing HCWB's risk profile alongside its fundamentals and technical indicators provides a more complete picture.